Detalles de la búsqueda
1.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
J Antimicrob Chemother
; 76(12): 3286-3295, 2021 11 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34450619
2.
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter.
Trials
; 22(1): 487, 2021 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34311777
3.
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial.
Trials
; 21(1): 544, 2020 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32560744
Resultados
1 -
3
de 3
1
Próxima >
>>